Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations.
about
Xenobiotic-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin modelsState-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiologyAnchoring molecular mechanisms to the adverse outcome pathway for skin sensitization: Analysis of existing data.Functional testing of topical skin formulations using an optimised ex vivo skin organ culture model.Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions.Potential applications of keratinocytes derived from human embryonic stem cells.Metabolic and redox barriers in the skin exposed to drugs and xenobiotics.Non-animal models of wound healing in cutaneous repair: In silico, in vitro, ex vivo, and in vivo models of wounds and scars in human skin.Development of a Full-Thickness Human Skin Equivalent In Vitro Model Derived from TERT-Immortalized Keratinocytes and Fibroblasts.Extracellular signal-regulated kinases 1/2 and Akt contribute to triclosan-stimulated proliferation of JB6 Cl 41-5a cells.Effect of Repeated Daily Dosing with 2,4-Dinitrochlorobenzene on Glutathione Biosynthesis and Nrf2 Activation in Reconstructed Human Epidermis.Comparative toxicological evaluation of nonylphenol and nonylphenol polyethoxylates using human keratinocytes.Biotransformation of 2,4-toluenediamine in human skin and reconstructed tissues.Human skin gene expression: Natural (trans) resveratrol versus five resveratrol analogs for dermal applications.An integrative test strategy for cancer hazard identification.Comparison of xenobiotic metabolizing enzyme activities in ex vivo human skin and reconstructed human skin models from SkinEthic.Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models
P2860
Q26825940-553673AB-0AEA-40BF-A302-279EF73CF296Q26852097-E13925B8-12D2-4608-ACD0-B8D688FF2014Q30835382-AE654298-1166-4FCE-AB45-7E2B50D9AAE8Q36994247-D5AD1338-00F8-4735-874B-80A058C893BAQ38155921-F9317B79-B123-41ED-8773-D3F2F1B62D2BQ38668504-A0837460-75A1-4174-BD52-49C4D3627931Q38725876-47CF2E1A-4098-4200-843C-35342FB79500Q38766135-046B0761-1716-4432-B16D-D0737A74BFD2Q38857654-AD3EA88C-654F-4729-B3E0-1049C6C00699Q38974584-FF87F132-1DD1-4650-B10D-366AE82E9932Q39523394-B1E12DA9-CB0E-4A96-94F2-60D0EE9D8D93Q47417474-DAA2EEDF-96CC-440C-AE1A-7AA362A3F248Q48366912-5B9F675F-902C-4C08-80D4-A051196548C0Q50431550-1D9A2730-F6F7-4B10-AD0D-FDB03D66D41AQ50856445-BC63559F-E7B7-42E1-8116-916AB14B2D5CQ53592187-0417605C-FBA8-4448-8EE1-8F7837CF8DADQ57095660-A9F110F7-2065-4F70-A8A2-3301A5D18415
P2860
Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Use of human in vitro skin mod ...... ent: metabolic considerations.
@en
Use of human in vitro skin mod ...... ent: metabolic considerations.
@nl
type
label
Use of human in vitro skin mod ...... ent: metabolic considerations.
@en
Use of human in vitro skin mod ...... ent: metabolic considerations.
@nl
prefLabel
Use of human in vitro skin mod ...... ent: metabolic considerations.
@en
Use of human in vitro skin mod ...... ent: metabolic considerations.
@nl
P2093
P2860
P356
P1476
Use of human in vitro skin mod ...... ent: metabolic considerations.
@en
P2093
Alain Latil
Carsten Goebel
Claire Moore
Daniel Duche
Ellen Fritsche
Gladys Ouédraogo
Joan Eilstein
Joao Barroso
Jochen Kuehnl
Julia Kenny
P2860
P304
P356
10.1093/TOXSCI/KFT080
P577
2013-03-28T00:00:00Z